1
|
Meis JM and Enzinger FM: Inflammatory
fibrosarcoma of the mesentery and retroperitoneum. A tumor closely
simulating inflammatory pseudotumor. Am J Surg Pathol.
15:1146–1156. 1991. View Article : Google Scholar : PubMed/NCBI
|
2
|
Coffin CM, Watterson J, Priest JR and
Dehner LP: Extrapulmonary inflammatory myofibroblastic tumor
(inflammatory pseudotumor). A clinicopathologic and
immunohistochemical study of 84 cases. Am J Surg Pathol.
19:859–872. 1995. View Article : Google Scholar : PubMed/NCBI
|
3
|
Gleason BC and Hornick JL: Inflammatory
myofibroblastic tumors: Where we are now? J Clin Pathol.
61:428–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lawrence B, Perez-Atayde A, Hibbard MK,
Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher
CD, et al: TPM3-ALK and TPM4-ALK oncogenes in inflammatory
myofibroblastic tumors. Am J Pathol. 157:377–384. 2000. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kovach SJ, Fischer AC, Katzman PJ, Salloum
RM, Ettinghausen SE, Madeb R and Koniaris LG: Inflammatory
myofibroblastic tumors. J Surg Oncol. 94:385–391. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
National Cancer Institute: Cancer Therapy
Evaluation Program: Common Toxicity Criteria. version 2.0.
March;1998.http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf
|
7
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, et al: New response evaluation criteria in
solid tumours: Revised RECIST guideline (version 1.1). Eur J
Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
U.S. Department of Health and Human
Services; National Institutes of Health. National Cancer Institute:
Common Terminology Criteria for Adverse Events (CTCAE). Version
4.0. May;2009.http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
|
9
|
Lucas DR, Shukla A, Thomas DG, Patel RM,
Kubat AJ and McHugh JB: Dedifferentiated liposarcoma with
inflammatory myofibroblastic tumor-like features. Am J Surg Pathol.
34:844–851. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Binh MB, Sastre-Garau X, Guillou L, de
Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I and Coindre JM:
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing
well-differentiated and dedifferentiated liposarcoma subtypes: A
comparative analysis of 559 soft tissue neoplasms with genetic
data. Am J Surg Pathol. 29:1340–1347. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Yamamoto H, Oda Y, Saito T, Sakamoto A,
Miyajima K, Tamiya S and Tsuneyoshi M: p53 Mutation and MDM2
amplification in inflammatory myofibroblastic tumors.
Histopathology. 42:431–439. 2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Butrynski JE, D'Adamo DR, Hornick JL, Dal
Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ,
Ramaiya N, et al: Crizotinib in ALK-rearranged inflammatory
myofibroblastic tumor. N Engl J Med. 363:1727–1733. 2010.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Bertocchini A, Lo Zupone C, Callea F,
Gennari F, Serra A, Monti L and de Ville de Goyet J: Unresectable
multifocal omental and peritoneal inflammatory myofibroblastic
tumor in a child: Revisiting the role of adjuvant therapy. J
Pediatr Surg. 46:E17–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Applebaum H, Kieran MW, Cripe TP, Coffin
CM, Collins MH, Kaipainen A, Laforme A and Shamberger RC: The
rationale for nonsteroidal anti-inflammatory drug therapy for
inflammatory myofibroblastic tumors: A children's oncology group
study. J Pediatr Surg. 40:999–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Przkora R, Bolder U, Schwarz S, Jauch KW,
Spes J, Andreesen R and Mackensen A: Regression of nonresectable
inflammatory myofibroblastic tumors after treatment with
nonsteroidal anti-inflammatory drugs. Eur J Clin Invest.
34:320–321. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kusunoki-Nakamoto F, Matsukawa T, Tanaka
M, Miyagawa T, Yamamoto T, Shimizu J, Ikemura M, Shibahara J and
Tsuji S: Successful treatment of an unresectable inflammatory
myofibroblastic tumor of the frontal bone using a cyclooxygenase-2
inhibitor and methotrexate. Intern Med. 52:623–628. 2013.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Johnson K, Notrica DM, Carpentieri D,
Jaroszewski D and Henry MM: Successful treatment of recurrent
pediatric inflammatory myofibroblastic tumor in a single patient
with a novel chemotherapeutic regimen containing celecoxib. J
Pediatr Hematol Oncol. 35:414–416. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Favini F, Resti AG, Collini P, Casanova M,
Meazza C, Trecate G and Ferrari A: Inflammatory myofibroblastic
tumor of the conjunctiva: response to chemotherapy with low-dose
methotrexate and vinorelbine. Pediatr Blood Cancer. 54:483–485.
2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
ESMO/European Sarcoma Network Working
Group: Soft tissue and visceral sarcomas: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25:iii102–iii112. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Mano H: ALKoma: A cancer subtype with a
shared target. Cancer Discov. 6:495–502. 2012. View Article : Google Scholar
|